330 related articles for article (PubMed ID: 19533723)
1. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
[TBL] [Abstract][Full Text] [Related]
2. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro.
Rocchi P; Jugpal P; So A; Sinneman S; Ettinger S; Fazli L; Nelson C; Gleave M
BJU Int; 2006 Nov; 98(5):1082-9. PubMed ID: 16879439
[TBL] [Abstract][Full Text] [Related]
3. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer.
Liu X; Liu C; Laurini E; Posocco P; Pricl S; Qu F; Rocchi P; Peng L
Mol Pharm; 2012 Mar; 9(3):470-81. PubMed ID: 22208617
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitory effect of silencing STAT3 gene with short hairpin RNA mediated by polyamidoamine dendrimers on growth of prostate cancer].
Zhao WM; Xiu YC; Xu Y; Wang YM; Cheng ZK; Yu Q; Kong DL
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):575-9. PubMed ID: 18210874
[TBL] [Abstract][Full Text] [Related]
5. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
6. An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo.
Yu T; Liu X; Bolcato-Bellemin AL; Wang Y; Liu C; Erbacher P; Qu F; Rocchi P; Behr JP; Peng L
Angew Chem Int Ed Engl; 2012 Aug; 51(34):8478-84. PubMed ID: 22829421
[TBL] [Abstract][Full Text] [Related]
7. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing.
Zhou J; Wu J; Hafdi N; Behr JP; Erbacher P; Peng L
Chem Commun (Camb); 2006 Jun; (22):2362-4. PubMed ID: 16733580
[TBL] [Abstract][Full Text] [Related]
8. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
9. Dendrimer Nanovectors for SiRNA Delivery.
Liu X; Peng L
Methods Mol Biol; 2016; 1364():127-42. PubMed ID: 26472447
[TBL] [Abstract][Full Text] [Related]
10. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents.
Perez AP; Romero EL; Morilla MJ
Int J Pharm; 2009 Oct; 380(1-2):189-200. PubMed ID: 19577619
[TBL] [Abstract][Full Text] [Related]
11. Promoting siRNA delivery via enhanced cellular uptake using an arginine-decorated amphiphilic dendrimer.
Liu X; Liu C; Zhou J; Chen C; Qu F; Rossi JJ; Rocchi P; Peng L
Nanoscale; 2015 Mar; 7(9):3867-75. PubMed ID: 25283447
[TBL] [Abstract][Full Text] [Related]
12. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
Gary DJ; Puri N; Won YY
J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
[TBL] [Abstract][Full Text] [Related]
13. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
Wang XL; Xu R; Lu ZR
J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).
Tsutsumi T; Hirayama F; Uekama K; Arima H
J Control Release; 2007 Jun; 119(3):349-59. PubMed ID: 17477999
[TBL] [Abstract][Full Text] [Related]
15. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
[TBL] [Abstract][Full Text] [Related]
16. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Liu B
Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
[TBL] [Abstract][Full Text] [Related]
17. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes.
Weber N; Ortega P; Clemente MI; Shcharbin D; Bryszewska M; de la Mata FJ; Gómez R; Muñoz-Fernández MA
J Control Release; 2008 Nov; 132(1):55-64. PubMed ID: 18727943
[TBL] [Abstract][Full Text] [Related]
18. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2006 Nov; 116(2):123-9. PubMed ID: 16831481
[TBL] [Abstract][Full Text] [Related]
19. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo.
Yagi N; Manabe I; Tottori T; Ishihara A; Ogata F; Kim JH; Nishimura S; Fujiu K; Oishi Y; Itaka K; Kato Y; Yamauchi M; Nagai R
Cancer Res; 2009 Aug; 69(16):6531-8. PubMed ID: 19654315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
